Neutralizing antibody titers reflect the immune system’s ability to block poliovirus from infecting cells, and they are a key correlate of protection against poliomyelitis. Protection against paralysis depends on having protective levels of these antibodies against all three poliovirus serotypes, because infection with any one serotype can cause poliomyelitis if there isn’t sufficient neutralizing antibodies for that serotype. So, high titers against each serotype mean individuals are protected from disease, not just from intestinal infection.

The main idea is that mass campaigns with the oral polio vaccine quickly stops the spread of wild poliovirus by boosting mucosal immunity across the community. OPV induces strong gut immunity, which reduces intestinal replication and viral shedding if infection occurs. When a large portion of the population is immunized in a short time, the number of susceptible people falls rapidly and transmission between people declines, often halting transmission chains in a matter of weeks to months. This is why such campaigns are effective at interrupting spread. While there are separate considerations about vaccine-derived poliovirus risk, the impact on wild poliovirus transmission from mass OPV campaigns is best described as rapid interruption of transmission, not a prolongation or no effect.

Management is supportive care focused on preserving breathing, preventing complications, and promoting recovery. Poliovirus damages motor neurons and there isn’t a proven antiviral that clears the infection, so treatment centers on what the body cannot yet do on its own. The immediate priority is the airway and adequate ventilation; many patients with paralytic polio can develop weakness of the respiratory muscles, so airway management and ventilatory support as needed are central. Along with that, careful fluid and nutrition support, prevention of pneumonia and other complications, and ongoing monitoring are important. Rehabilitation plays a crucial role in recovery since nerve and muscle function can gradually return or improve with therapy, even though damage to neurons is permanent in many cases. Physical and occupational therapy help regain strength, mobility, and independence over time. Immunoglobulin therapy or antiviral drugs are not part of standard acute management for poliomyelitis.

Measuring progress toward polio eradication relies on multiple indicators that capture both surveillance quality and the actual status of virus transmission. Non-polio AFP rates are used to gauge how sensitive the AFP surveillance system is—if many non-polio AFP cases are detected, it suggests the system is likely catching poliovirus cases if they occur. Adequacy of stool specimens ensures that the collected samples are relevant and properly collected, which is essential for accurate lab confirmation of poliovirus. Environmental surveillance results, obtained from sewage testing, can reveal poliovirus circulation even when clinical cases aren’t identified, providing an early warning of transmission. Vaccination coverage reflects how well the population is immune, with higher coverage reducing the risk of outbreaks. Ultimately, interruption of wild-type poliovirus transmission confirms that the virus is no longer circulating in the population. Together, these indicators give a complete picture of progress toward eradication, so the best choice includes all of them.